Ligand Pharmaceuticals saw the highest growth of 149% in patent filings in November and 399% in grants in October in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 99% and grants by 399%. GlobalData’s DataBook provides a comprehensive analysis of Ligand Pharmaceuticals‘s patent filings and grants. Buy the databook here.

Smarter leaders trust GlobalData

Ligand Pharmaceuticals has been focused on protecting inventions in United States(US) with six publications in Q4 2023

The United States(US) Patent Office dominates the patent filings and grants with nearly 33% filings and 57% grants. The United States(US), Japan(JP), European Patent Office(EPO), and China(CN) patent Office are among the top ten patent offices where Ligand Pharmaceuticals is filings its patents. Among the top granted patent authorities, Ligand Pharmaceuticals has 57% of its grants in United States(US), 14% in Japan(JP) and 14% in Spain(ES).

For comprehensive analysis of Ligand Pharmaceuticals's filings and grants, buy the databook here.

This content was updated on 14 July 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.

Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.